Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nilotinib is safe in moderate and advanced Parkinson’s disease

Publish date:: May 29, 2020

Key clinical point: Nilotinib is safe and tolerable in patients with moderate or advanced Parkinson’s disease.

Major finding: One treatment-related serious adverse event occurred; the patient was in the 300-mg/day group.

Study details: A randomized, double-blind, placebo-controlled, parallel-group study of nilotinib in 76 patients with Parkinson’s disease.

Disclosures: The Michael J. Fox Foundation, the Cure Parkinson’s Trust, and Van Andel Research Institute funded the study. Novartis provided the study drug and placebo. The investigators reported no conflicts of interest.

Citation:

Simuni T et al. AAN 2020. Abstract 43617.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Movement Disorders

Blood biomarker may predict Parkinson’s disease progression,

Can DBS in early Parkinson’s disease reduce disease progression?,

Huntington's disease biomarkers appear 24 years before clinical symptoms,

Nilotinib is safe in moderate and advanced Parkinson’s disease,

GI symptoms in Parkinson’s disease correlate with less microbial diversity,